Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Verona Pharma Plc ADR’s stock clocked out at $94.4, down -0.75% from its previous closing price of $95.11. In other words, the price has decreased by -$0.75 from its previous closing price. On the day, 0.79 million shares were traded. VRNA stock price reached its highest trading level at $95.98 during the session, while it also had its lowest trading level at $93.57.
Ratios:
To gain a deeper understanding of VRNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.73 and its Current Ratio is at 8.86. In the meantime, Its Debt-to-Equity ratio is 1.08 whereas as Long-Term Debt/Eq ratio is at 1.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on April 28, 2025, initiated with a Buy rating and assigned the stock a target price of $100.
On April 21, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $80.
On January 10, 2025, ROTH MKM started tracking the stock assigning a Buy rating and target price of $68.ROTH MKM initiated its Buy rating on January 10, 2025, with a $68 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 16 ’25 when Fisher Andrew sold 80,000 shares for $11.53 per share. The transaction valued at 922,000 led to the insider holds 359,999 shares of the business.
Hahn Mark W sold 400,000 shares of VRNA for $4,560,360 on Jun 11 ’25. The Chief Financial Officer now owns 12,278,992 shares after completing the transaction at $11.40 per share. On Jun 11 ’25, another insider, ZACCARDELLI DAVID, who serves as the President and CEO of the company, sold 400,000 shares for $11.40 each. As a result, the insider received 4,560,520 and left with 13,190,168 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRNA now has a Market Capitalization of 8022007808 and an Enterprise Value of 68673740800. For the stock, the TTM Price-to-Sale (P/S) ratio is 67.79 while its Price-to-Book (P/B) ratio in mrq is 35.47. Its current Enterprise Value per Revenue stands at 579.354 whereas that against EBITDA is -513.867.
Stock Price History:
The Beta on a monthly basis for VRNA is 0.23, which has changed by 5.528354 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, VRNA has reached a high of $99.01, while it has fallen to a 52-week low of $14.14. The 50-Day Moving Average of the stock is 23.06%, while the 200-Day Moving Average is calculated to be 73.85%.
Shares Statistics:
It appears that VRNA traded 1.41M shares on average per day over the past three months and 1039510 shares per day over the past ten days. A total of 85.13M shares are outstanding, with a floating share count of 76.70M. Insiders hold about 9.90% of the company’s shares, while institutions hold 76.23% stake in the company. Shares short for VRNA as of 1749772800 were 8415794 with a Short Ratio of 5.95, compared to 1747267200 on 8068371. Therefore, it implies a Short% of Shares Outstanding of 8415794 and a Short% of Float of 10.31.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
